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In 2003, severe acute respiratory syndrome coronavirus (SARS-CoV) emerged and caused over 8,000 human
cases of infection and more than 700 deaths worldwide. Zoonotic SARS-CoV likely evolved to infect humans by
a series of transmission events between humans and animals for sale in China. Using synthetic biology, we
engineered the spike protein (S) from a civet strain, SZ16, into our epidemic strain infectious clone, creating
the chimeric virus icSZ16-S, which was infectious but yielded progeny viruses incapable of propagating in vitro.
After introducing a K479N mutation within the S receptor binding domain (RBD) of SZ16, the recombinant
virus (icSZ16-S K479N) replicated in Vero cells but was severely debilitated in growth. The in vitro evolution
of icSZ16-S K479N on human airway epithelial (HAE) cells produced two viruses (icSZ16-S K479N D8 and
D22) with enhanced growth on HAE cells and on delayed brain tumor cells expressing the SARS-CoV receptor,
human angiotensin I converting enzyme 2 (hACE2). The icSZ16-S K479N D8 and D22 virus RBDs contained
mutations in ACE2 contact residues, Y442F and L472F, that remodeled S interactions with hACE2. Further,
these viruses were neutralized by a human monoclonal antibody (MAb), S230.15, but the parent icSZ16-S
K479N strain was eight times more resistant than the mutants. These data suggest that the human adaptation
of zoonotic SARS-CoV strains may select for some variants that are highly susceptible to select MAbs that bind
to RBDs. The epidemic, icSZ16-S K479N, and icSZ16-S K479N D22 viruses replicate similarly in the BALB/c
mouse lung, highlighting the potential use of these zoonotic spike SARS-CoVs to assess vaccine or serotherapy
efficacy in vivo.
Diseases caused by emerging viruses such as human immu-
nodeficiency virus, Ebola virus, influenza virus H5N1, West
Nile virus, and dengue virus have had a profound impact on
global public health (28). In 2003, a novel coronavirus, severe
acute respiratory syndrome coronavirus (SARS-CoV), emerged
suddenly as the causative agent of SARS and spread world-
wide, causing about 8,000 cases and 700 deaths (3, 17, 41).
SARS-CoV most likely evolved from viruses circulating within
the Chinese horseshoe bat and other bat species that are be-
lieved to be the natural animal reservoirs (18). Within live-
animal markets in the Guangdong region of China, it is hy-
pothesized that the close cohabitation of bats and palm civets
allowed for subsequent cross-species transmission and ampli-
fication of bat strains in civets (9, 18). Palm civets then served
as an intermediate host for the subsequent viral evolution of
strains that could infect and transmit between humans (18).
Clinical data suggest that the sporadic early human SARS-
CoV infections were significantly less pathogenic than later
ones and that a progressive series of adaptive mutations was
necessary for increased human-to-human transmission and the
expanding phases of the epidemic (2, 9, 41). Despite initial
reports that civet strains SZ16 and SZ3 could be propagated in
cell culture, subsequent studies have indicated that these vi-
ruses could not be successfully maintained in culture, thereby
hampering our understanding of their pathogenicities and
mechanisms of cross-species transmission in humans (19).
Within the past 4 years, multiple newly emerging coronavi-
ruses of human relevance have been identified, highlighting the
emerging disease potential of the coronavirus family (35, 41,
50, 53). SARS-CoV and human coronavirus HKU1 are newly
emerging members of coronavirus genogroup II, and both
cause pneumonic disease in humans, with SARS-CoV being
the most pathogenic of the known human coronaviruses (7, 17,
41, 52, 53). Viruses related to the SARS-CoV epidemic strain
have recently been found in Chinese horseshoe bats during
surveillance of wild animals in Hong Kong (18). Since viruses
similar to the epidemic strain have been found circulating
within zoonotic pools, there is the potential for yet another
reemergence (18). Moreover, a promiscuous RNA-dependent
RNA polymerase coupled with high-frequency recombination
rates makes the evolution of future human coronavirus patho-
gens a real possibility (6, 36, 57).
The coronavirus spike glycoprotein (S) is a key determinant
of host specificity, and elucidating the molecular mechanisms
of viral host expansion may help us understand the events that
rendered SARS-CoV pathogenic to humans (16, 24). Virus
sequence data isolated throughout the course of the epidemic
suggest that the S gene was under heavy positive selection
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during the early phase of the epidemic but eventually stabilized
as the epidemic progressed (2). The S protein is 1,225 amino
acids (aa) in length and can be divided into two main func-
tional domains, S1 and S2. The S1 region (aa 17 to 756)
contains the receptor binding domain (RBD; aa 318 to 510),
while the S2 region (aa 757 to 1225) contains the two heptad
repeat regions responsible for viral fusion and a transmem-
brane domain (aa 1189 to 1227) that anchors S to the viral
envelope. SARS-CoV entry into the host cell is mediated by a
receptor, angiotensin I converting enzyme 2 (ACE2), and per-
haps other coreceptors (15, 22). ACE2 has been detected on
the apical surfaces of ciliated cells within the lung epithelia as
well as in the kidneys and colon (12). After S and receptor
binding, the virus enters the cell by receptor-mediated endo-
cytosis. Cleavage of the SARS-CoV S by cathepsin L within the
endosome is required for SARS-CoV infection and precedes
fusion (42).
Sequences isolated throughout the initial epidemic from
2002 to 2003 and during the reemergence from 2003 to 2004
chronicle the mutations in S that may have allowed for host
expansion. During the epidemic and the reemergence, the
early 2003 SARS-CoV animal isolate, SZ16, and the 2004
reemergent human isolate, GD03, were among the most diver-
gent viruses isolated from civets and humans, respectively.
SARS-CoV SZ16 was identified in palm civets in live-animal
markets within the Guangdong region of China during the
epidemic, and its S protein differs from that of the epidemic
strain, SARS Urbani, in 18 amino acids, 16 of which reside in
the S1 domain. Using pseudotyped viruses, recent work has
shown that the mutation of residue 479 within the SZ16 RBD
was sufficient to allow for the host range expansion of zoonotic
SARS-CoV spike-bearing pseudovirus to infect human cells
(21, 24).
In this study, we describe the synthetic construction and
characterization of a SARS-CoV chimera bearing a zoonotic
SZ16 S protein. Importantly, we find that the mutations ac-
quired during the in vitro evolution of a zoonotic, S-bearing
recombinant virus in human airway epithelial (HAE) cells can
vary from those that occurred during the epidemic, highlight-
ing the adaptive plasticity of the zoonotic S protein. Also, these
data suggest that HAE cells can be used as a model to evaluate
the possible avenues of SARS-CoV zoonotic S evolution to-
ward the efficient infection of human cells. Lastly, recombinant
viruses bearing zoonotic S proteins replicated efficiently in
mice and will serve as a valuable tool in assessing the efficacies
of vaccines and therapies.
MATERIALS AND METHODS
Viruses and cells. The recombinant epidemic virus strain “icSARS” (GenBank
accession no. AY278741), icSZ16-S (GenBank accession no. AY304488), and the
icSZ16-S K479N, icSZ16-S K479N D8, and icSZ16-S K479N D22 mutant strains
were propagated on Vero E6 cells as described previously (58). Virus stocks used
throughout this study were grown and titers were determined by plaque assays
with Vero E6 cells as described previously (58). Vero E6 and delayed brain
tumor (DBT) cells were grown in minimal essential medium (Invitrogen, Carls-
bad, CA) supplemented with 10% FCII (HyClone, South Logan, UT) and gen-
tamicin/kanamycin (UNC Tissue Culture Facility). Mink lung epithelial cells
(Mv1lu) were grown in Dulbecco’s minimal essential medium (Invitrogen, Carls-
bad, CA) supplemented with 10% FCII (HyClone, South Logan, UT) and gen-
tamicin/kanamycin (UNC Tissue Culture Facility). HAE cells were obtained
from airway tissues harvested from patients undergoing elective surgery accord-
ing to the UNC Institutional Review Board-approved protocols of the UNC
Cystic Fibrosis Center Tissue Culture Core. Briefly, primary cells were expanded
on plastic to generate passage 1 cells and plated at a density of 250,000 cells per
well on permeable Transwell-Col (12-mm-diameter) supports (8, 33). HAE cell
cultures were generated by the provision of an air-liquid interface for 4 to 6
weeks to form well-differentiated, polarized cultures that resemble in vivo pseudo-
stratified mucociliary epithelia (33). All virus work was performed in a class II
biological safety cabinet in a certified biosafety level 3 laboratory containing
redundant exhaust fans and by laboratorians wearing Tyvek suits and powered
air-purifying respirators as described previously (56).
Construction of chimeric SARS-CoVs bearing the SZ16 spike protein
icSZ16-S. The infectious clone of the epidemic strain from R. Baric’s laboratory
is divided into six subgenomic cDNA clones (A to F) that span the SARS-CoV
genome. The first two-thirds of the S gene is located within the icSARS E
fragment (nucleotides [nt] 21492 to 24056), and the last third is located within
the icSARS F fragment (nt 24057 to 25259). A synthetic DNA containing SZ16
nt 21541 to 24056 was purchased from Blue Heron Technology (Bothell, WA).
The fragment was digested with AgeI and XbaI (NEB, Ipswich, MA) and cloned
into the existing icSARS-E pSMART plasmid, replacing the Urbani S glycopro-
tein with the SZ16 variant sequence to create icSZ16-E pSMART. Within the
SARS F fragment, the two remaining coding changes of the SZ16 S were
introduced via PCR and the class II restriction enzyme AarI. Briefly, three
amplicons, A, B, and C, were generated by PCR using Expand high-fidelity
polymerase (Roche, Indianapolis, IN). The primer pairs used are as follows:
amplicon A, PasIF (5-CTGTTTTCCCTGGGATCGC-3) and AarIM1NR (5-
NNNNNNCACCTGCTTTTGGGCAACTCCAATGCC-3); amplicon B,
AarIM1NF (5-NNNNNNCACCTGCAGTTGCCCAAAATGTTCTCTATGA
GAAC-3) and AarIM2NR (5-NNNNNNCACCTGCATTTCTTCTTGAATG
TTGACGACAGAAG-3); and amplicon C, AarIM2NF (5-NNNNNNCACCT
GCTCAAGAAGAAATTGACCGCCTC-3) and BamHIR (5-CATAAATTG
GATCCATTGCTGG-3). Amplicons A, B, and C were digested with AarI for
1.5 h at 37°C (Fermentas, Burlington, Ontario, Canada), gel purified, and ligated
to create the fragment ABC. The ABC ligation products were gel purified, and
TA was cloned into TOPO-XL (Invitrogen, Carlsbad, CA) to create pTOPO-XL
ABC. The pTOPO-XL ABC subclones were confirmed by sequencing.
pTOPO-XL ABC was BamHI digested at 37°C for 1 h, which released a 2,059-nt
fragment containing the icSZ16 F fragment S sequence. icSARS F-pSMART was
digested with BamHI at 37°C for 1 h, which excised the epidemic strain S
sequence and released a 5,749-bp vector fragment. The 2,059-bp SZ16 insert and
the 5,749-bp vector fragments were gel purified using a QIAquick gel purification
kit (Qiagen, Valencia, CA) and ligated (NEB, Ipswich, MA) to create icSZ16
F-pSMART.
Construction of the chimeric icSZ16-S K479N mutant. The icSZ16-E
pSMART sequence for S residue 479 was mutated from lysine (AAA) to an
asparagine (AAT) using overlap PCR. Amplicon A (NcoIF [5-TGTTTCTAA
ACCCATGGGTACACAG-3] and SZ16479R [5-CCATAATCATTTAATGG
CCAATAAC-3]) and amplicon B (SZ16479NF [5-GTTATTGGCCATTAAA
TGATTATGG-3] and XbaIR [5-GGGCCCTCTAGAGATCGAGC-3]) were
generated using Expand high-fidelity polymerase (Roche, Indianapolis, IN). To
join the fragments, amplicons A (1,010 bp) and B (1,153 bp) were used as
templates in overlapping PCR with primers NcoIF and XbaIR. The final AB
amplicon was purified using a Qiagen PCR purification kit (Qiagen, Valencia,
CA) and digested with NcoI and XbaI (NEB, Ipswich, MA) for 1 h at 37°C. The
digested amplicon (2.2 kb) was gel purified using a QIAquick gel purification kit
(Qiagen, Valencia, CA), ligated to the 5.3-kb NcoI/XbaI fragment of icSARS
SZ16-E pSMART, and sequence verified.
Isolation of recombinant viruses. From the ligation of appropriate infectious
clone fragments, icSZ16-S or icSZ16-S K479N full-length chimeric cDNA was
generated, and full-length transcripts were synthesized, mixed with polyadenyl-
ated N gene transcripts, and then electroporated into cells as previously de-
scribed (56). Clarified supernatants from the icSZ16-S or icSZ16-K479N elec-
troporations were passaged onto naive Vero E6 cells to confirm the presence of
replicating virus. If a cytopathic effect (CPE) was not detected, viruses were
passaged every 48 h onto Vero E6 cells until cytopathology was observed. With
icSZ16-S K479N, a mild CPE was observed at passage 3 (p3), and a more robust
CPE was seen by p6. The icSZ16-S K479N p3 and p6 viruses were plaque purified
in Vero E6 cells. The S, 3a, E, and M genes of the recombinant viruses were
sequence verified, and stocks were grown in T75 flasks and stored at 80°C for
future use.
RT-PCR to detect the subgenomic leader containing transcripts. Reverse
transcriptase (RT)-PCR to detect the subgenomic leader containing transcripts
was performed to demonstrate viral replication. RNA from virus-infected cells
was isolated using TRIzol reagent (Invitrogen, Carlsbad, CA), according to
protocol. One to five micrograms of total RNA was used to generate cDNA by
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Superscript II (Invitrogen, Carlsbad, CA), using random hexamer primers (In-
vitrogen, Carlsbad, CA). cDNA was then used as a template for the PCR using
Taq polymerase (NEB, Ipswich, MA) with a leader forward primer (CTCTTG
TAGATCTGTTCTCTAAACGAAC) and a reverse primer in the M gene (TT
ACTGTACTAGCAAAGCAATATTGTCG). The detection of glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) (primer GAPDHF [5-CATGGGGAA
GGTGAAGGTCG-3] and primer GAPDHR [5-TTGATGGTACATGACAA
GGTGC-3]) messages by RT-PCR was done as a positive control. The PCR
products were separated by gel electrophoresis on 1.8% agarose–Tris-acetate-
EDTA gels and visualized by ethidium bromide staining.
In vitro evolution of icSARS SZ16 K479N in HAE cell cultures for 22 days.
HAE cell cultures were created as described previously (43). The cultures were
infected with 105 PFU of icSARS K479N in a 200-l volume. After a 2-h
infection, the inoculum was removed, and the cells were washed briefly with
Dulbecco’s phosphate-buffered saline (DPBS) and then maintained for 4 days.
After 4 days of infection, the apical surfaces of the cultures were rinsed, and
supernatants were placed onto the apical surfaces of fresh cultures for 1 h,
washed, and maintained for another 4 days. Apical washes were then plaque
purified to isolate the icSZ16-S K479N D8 virus. A total of 200 l of day 8
supernatants was used to infect naive HAE cell cultures as described above, and
the cultures were passaged two additional times at 4-day intervals and then three
times every 48 h to preferentially enrich for more efficiently replicating virus
variants. After 22 days of selection for efficient growth in HAE cells, the apical
surfaces were rinsed and the supernatants were plaque purified to isolate the
icSZ16-S K479N D22 virus. Plaques were expanded on 60-mm dishes, and RNA
was isolated using TRIzol (Invitrogen Carlsbad, CA). Amplicons spanning from
the S, 3a, E, and M genes were generated by RT-PCR and directly sequenced.
Generation of hACE2-expressing DBT cells. A plasmid carrying an N-terminal
myc-tagged human ACE2 (hACE2) was kindly donated by M. Farzan of Harvard
Medical School. The hACE2 gene was amplified by PCR using Expand high-
fidelity polymerase (Roche, Indianapolis, IN) (ACE2For [5-CACCATGTCAA
GCTCTTCCTGGCTCC-3] and ACE2Rev [5-CTAAAAGGAGGTCTGAAC
ATCATCAGTG-3]). Amplicons were gel purified using the QIAquick gel
purification kit (Qiagen, Valencia, CA) and cloned into pcDNA3.1/V5-His (In-
vitrogen, Carlsbad, CA) according to protocol to create pcDNA3.1/V5-His
hACE2. The ACE2 gene plasmid was sequence verified. DBT cells were trans-
fected with 4 g of pcDNA3.1/V5-His hACE2 using Fugene reagent (Roche,
Indianapolis, IN). After 24 h, the cells were placed under drug selection using
700 g/ml of G418 (Invitrogen, Carlsbad, CA) in complete growth medium and
remained under drug selection throughout all experiments. The cells were pas-
saged four times, sorted for high ACE2 expression by flow cytometry, and then
expanded under drug selection before use.
Growth curve analysis of HAE, Vero E6, DBT hACE2, or DBT cells. HAE cells
were infected with 4.4  104 PFU of the recombinant epidemic strain icSARS,
icSZ16-S K479N p3, icSZ16-S K479N D8, or icSZ16-S K479N D22 for 2 h at
37°C, after which the inoculum was removed and the apical surface rinsed with
DPBS. At 0, 6, 12, 24, 36, 48, and 72 h postinfection (hpi), the apical surfaces of
the HAE cells were rinsed with 200 l DPBS and the samples stored at 80°C
until titration by plaque assay. Vero E6 and DBT hACE2 cells were infected with
icSARS, icSZ16-S K479N p3, icSZ16-S K479N p6, icSZ16-S K479N D8, or
icSZ16-S K479N D22 at a multiplicity of infection (MOI) of 0.01 for 1 h at 37°C,
after which the inoculum was removed, the monolayer was rinsed with DPBS,
and growth medium was added. DBT cells were infected in a similar manner and
with the same panel of viruses as the Vero E6 and DBT hACE2 cells, except that
icSZ16-S K479N p3 was excluded from the experiment. The cell media were
sampled at 0, 6, 12, 24, and 36 hpi, and the samples were stored at 80°C until
titers were determined by plaque assay (56). The growth curve data presented
are representative of two separate experiments.
Immunohistochemistry of infected HAE cells. To detect SARS-CoV antigens
in HAE cells, infected or mock-infected cultures were fixed in 4% paraform-
aldehyde (PFA) for 24 h, transferred to 70% ethanol, and prepared as paraffin-
embedded histological sections by the UNC Cystic Fibrosis Center Morphology
and Morphometrics Core. After deparaffinization, histological sections were
incubated for 1 h in PBS containing 3% bovine serum albumin. Primary anti-
bodies directed against SARS N or tubulin were applied at a 1:100 dilution in
PBS with 1% bovine serum albumin overnight and detected with fluorescein
isothiocyanate or Texas Red secondary antibodies (anti-mouse antibodies con-
jugated to Texas Red; Jackson ImmunoResearch). Immunofluorescence was
visualized with a Leica Leitz DMIRB inverted fluorescence microscope equipped
with a cooled-color, charge-coupled digital camera (MicroPublisher, Q-Imag-
ing). A tricolor filter cube set (green fluorescent protein-Texas Red-DAPI [4,6-
diamidino-2-phenylindole]) was used to show the morphology of the tissue sec-
tion (by combining low autofluorescence levels across the three filters), thus
aiding the determination of fluorescent-antibody localization to specific regions
of the cells.
Plaque reduction neutralization titer assay. Neutralizing titers were deter-
mined by plaque reduction neutralization titer assay (PRNT) (40). Twenty-four
hours prior to infection, six-well plates were seeded with 5  105 Vero E6
cells/well. A human monoclonal antibody (MAb), S230.15, directed against the
SARS-CoV RBD and an isotype control antibody, D2.2, directed against cholera
toxin were kindly provided by A. Lanzavecchia. The MAbs were serially diluted
twofold and incubated with 100 PFU of either icSARS, icSZ16-S K479N p6,
icSZ16-S K479N D8, or icSZ16-S K479N D22 for 1 h at 37°C. Virus and anti-
bodies were then added to six-well plates of Vero E6 cells in duplicate and
incubated at 37°C for 1 h, after which the cells were overlaid with 3 ml of 0.8%
agarose in medium. The plates were incubated for 48 h at 37°C and stained with
neutral red for 3 h, and the plaques were counted. The percentages of neutral-
ization were calculated as follows: 1 (number of plaques with antibody/number
of plaques without antibody)  100%.
Infection of 6-week-old and senescent BALB/c mice. Six-week-old female
BALB/c mice (Charles River, Wilmington, MA) or 12-month-old female
BALB/c mice were anesthetized with a ketamine and xylazine mixture adminis-
tered intraperitoneally in a 50-l volume. Each mouse was inoculated with 1 
105 PFU/50 l of icSARS, icSZ16-S K479N p6, or icSZ16-S K479N D22 intra-
nasally (10 mice for each virus for the 6-week-old animals; 12 mice for each virus
for the 12-month-old animals), and weight was monitored daily for 4 days postin-
fection. On days 2 and 4, three mice per group were sacrificed by isoflurane
overdose, and the lungs were removed for virus titer determination. One-half of
each lung was frozen at 80°C until titration by plaque assay. The lungs were
weighed and homogenized, and PBS was added to generate a 20% solution. The
solution was then clarified by centrifugation and serially diluted for use in a
standard plaque assay with Vero E6 cells (56).
Phylogenetic analysis of SARS-CoV spikes and computer modeling. Nucleo-
tide and protein sequence alignments of Urbani (GenBank accession no.
AY27841), HKU3 (GenBank accession no. DQ022305), HC/SZ/61/03 (GenBank
accession no. AY515512), SZ16 (GenBank accession no. AY304488), GD03
(GenBank accession no. AY525636), GZ02 (GenBank accession no. AY390556),
and CUHK-W1 (GenBank accession no. AY278554) were created using ClustalX
v1.83 (37). A neighbor joining tree was generated from the ClustalX nucleotide
sequence alignment, bootstrapped 1,000 times, and exported into TreeView to
create neighbor joining tree graphics (31). The numbers at each node represent
the corresponding bootstrap values.
The crystal structure coordinates of the SARS-CoV RBD interacting with the
hACE2 receptor (PDB code 2AJF) were used as a template to generate each set
of mutations using the Rosetta Design web server (http://rosettadesign.med.unc
.edu/) (21). In each case, the SARS-CoV RBD structure was analyzed using the
molecular modeling tool MacPyMol (DeLano Scientific) to determine which
amino acids were proximal to the amino acid(s) being targeted for replacement.
Briefly, each amino acid to be altered was highlighted, and all other amino acids
within an interaction distance of 5 angstroms were identified. Using the Rosetta
Design website, the amino acid replacements were incorporated, and all amino
acids within the 5-angstrom interaction distance were relaxed to allow the pro-
gram to repack the side chains to an optimal energetic state. This process was
repeated for each mutation and series of mutations. Ten models were generated
for each set of mutations, and the best model, based on the lowest energy score,
was selected and further evaluated using MacPyMol.
RESULTS
Construction and characterization of icSZ16-S and
icSZ16-S K479N viruses. Public genetic databases and syn-
thetic biology were harnessed to rapidly translate electronic
S gene sequence information into S gene DNA fragments.
The SZ16 virus was isolated in live-animal markets in China,
and its sequence was published in 2003. When nucleotide
sequences of S proteins isolated over the course of the
epidemic are compared, the SZ16 S is similar to viruses
isolated from Chinese horseshoe bats (HKU3) and to the
evolved human-adapted strains (Fig. 1A). The SZ16 S dif-
fers from that of the epidemic strain in 18 amino acid po-
sitions, 16 of which reside in the S1 region and may well
represent the progenitor strains for the 2003 human epi-
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demic. Much of the SZ16 sequence variability maps in and
around the three known neutralizing epitopes marked as
regions A, B, and C in Fig. 1B, suggesting that human MAbs
derived from human SARS-CoV infections might be less
efficacious against SZ16 early civet isolates. As the SZ16
virus could not be successfully maintained in culture, we
used synthetic biology and reverse genetics to molecularly
resurrect a recombinant and genetically modifiable SARS-
CoV bearing the SZ16 S glycoprotein (icSZ16-S) (Fig. 1C).
Although icSZ16-S recombinant virus infection was not ev-
ident by cytopathology-based assays or by plaque assay, RT-
PCR confirmed the presence of virus replication within the
electroporated cell culture by detecting the subgenomic lead-
ers containing transcripts for open reading frames 3a, E, and M
FIG. 1. Phylogenetic relationships of zoonotic SARS-CoV and construction of zoonotic spike protein chimeras within the SARS-CoV
infectious clone. The colors in panels A, B, and C denote the phase of the SARS-CoV epidemic at which the viruses or amino acid residues evolved:
blue, animal associated; yellow, early phase; orange, middle phase; and red, late phase. (A) Neighbor joining tree constructed from nucleotide
sequences of various SARS-CoV S genes. The numbers represent bootstrap values based on 1,000 bootstrap replicates. (B) Spike protein amino
acid differences between Urbani, GD03, and SZ16. Known neutralizing epitopes are denoted A, B, and C. (C) Schematic of infectious clone
fragments A to F and the SARS-CoV genes contained therein. Using synthetic biology and site-directed mutagenesis, we reconstructed the SZ16
S that was then inserted into our infectious clone, replacing the epidemic strain S.
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(Fig. 2A). The transfer of the icSZ16-S supernatants from the
electroporated cell culture to a naive Vero E6 or a mink lung
epithelial (Mv1Lu) cell culture did not result in a productive
infection, as the leader containing transcripts was not detected
(Fig. 2B). As a positive control, we passaged icSARS superna-
tants to Vero E6 and Mv1Lu cell cultures, and both infections
resulted in detectable wild-type virus replication by RT-PCR
(Fig. 2B).
Since the icSZ16-S genomic RNA was capable of replicating
in Vero E6 cells but the progeny virions were incapable of
reinfection and amplification, we hypothesized that the infec-
tion was blocked due to inefficient S glycoprotein and ACE2
receptor interaction. In 2005, Li et al. crystallized the RBD of
SARS-CoV bound to ACE2 and proposed that residues 479
and 487 of the civet S inhibited efficient usage of the hACE2
receptor (21). Using site-directed mutagenesis, we changed
residue 479 of the SZ16 S from lysine to the more human
tropic asparagine (K479N) and constructed and recovered the
recombinant virus (icSZ16-S K479N). Unlike icSZ16-S virus
infection, icSZ16-S K479N infection could be passed on to
Vero E6 cell cultures by the transfer of supernatants to naive
cell cultures (Fig. 2C), providing direct support for the hypoth-
esis that SZ16 infection of human and/or primate cells is
blocked by the civet S residue at position 479.
In vitro evolution of icSZ16-S K479N virus in primary HAE
cell cultures. Zoonotic reintroductions represent the most
likely mechanism for the reemergence of epidemic SARS-CoV
strains in human populations. The SZ16 S K479N mutation
permitted binding and entry into primate cells, but our prelim-
inary data suggested that infections of HAE were inefficient
(data not shown). To select for civet viruses with enhanced
growth in HAE cells, cultures were apically infected with
icSZ16-S K479N and maintained and passaged for a total of 22
days. The virus isolated after 8 days in culture, icSZ16-S
K479N D8, contained one mutation from tyrosine to phenyl-
alanine at position 442 within the RBD (Y442F). The virus
recovered after 22 days in culture, icSZ16-S K479N D22, con-
tained the Y442F mutation as well as an additional mutation
within the RBD from leucine to phenylalanine at position 472
(L472F). No other coding mutations were found in the S, 3a, E,
or M genes. Interestingly, both 442 and 472 are contact resi-
dues between S and ACE2 according to the reported crystal
structure (21).
The evolved icSZ16-S K479N D8 and D22 viruses exhibit
growth kinetics similar to those of the wild type in various cell
types. The growth fitness of icSARS, icSZ16-S K479N p3, and
the HAE-cell-evolved icSZ16-S K479N D8 and D22 viruses
was assessed with HAE cells, Vero E6 cells, murine DBT cells
stably expressing hACE2, and nonpermissive murine DBT
cells. HAE cell cultures were infected with 4.4  104 PFU of
virus for 2 h and then rinsed, and apical wash samples were
taken at various intervals over 72 hpi to monitor virus growth.
The epidemic strain, icSARS, grew to peak titers approaching
107 PFU/ml by 72 hpi (Fig. 3A). icSZ16-S K479N p3 grew
poorly in the HAE cell cultures, with peak titers reaching only
103 PFU/ml (Fig. 3A). Compared to the epidemic strain, the
icSZ16-S K479N D22 virus grew with similar growth kinetics at
early time points, but peak titers were reduced by about 1 log
and approached106 PFU/ml by 72 hpi (Fig. 3A). The growth
of the icSZ16-S K479N D8 virus lagged at early time points but
recovered to peak titers similar to that of the icSZ16-S K479N
D22 virus (Fig. 3A). In Vero E6 cells, the epidemic strain and
the icSZ16-S K479N D22 virus reached peak titers of 107
PFU/ml 24 hpi, while icSZ16-S K479N D8, icSZ16-S K479N
p3, and icSZ16-S K479N p6 grew to 105 PFU/ml (Fig. 3B).
To model the SARS S and hACE interactions within the
primary HAE cells and to prove that these mutations were
influencing docking and entry via hACE2, we constructed DBT
cells that stably express hACE2. In comparison to those of
HAE cells, viral growth kinetics were more rapid in DBT-
hACE2, although the overall trends in growth among viruses
were more or less conserved. In DBT-hACE2 cells, icSARS
replicated to peak titers of 107 PFU/ml by 24 hpi and then
diminished over time to 106 PFU/ml by 36 hpi (Fig. 3C).
FIG. 2. SARS-CoV SZ16 spike protein chimera icSZ16-S replicates in Vero E6 cells, but infection cannot be passed in culture until a point
mutation (K479N) is introduced within the RBD. The expected sizes of the target RT-PCR products are as follows: for 3a, 1,796 bp; E, 949 bp;
M, 666 bp; and GAPDH, 235 bp. (A) RT-PCR for the leader containing transcripts detects actively replicating genomic RNA. RT-PCR using RNA
extracted from Vero E6 cells transfected with genomic icSZ16-S RNA (passage 0) detects transcripts for the E and M genes of icSZ16-S. (B) The
transfer of icSZ16-S supernatants from passage 0 to naive Vero E6 or mink lung epithelial Mv1Lu cells does not result in a productive infection.
As a positive control, Vero E6 and Mv1Lu cells were successfully infected with epidemic strain supernatants, as replication was detected by the
presence of the leader containing transcripts. (C) In contrast to wild-type icSZ16-S, a point mutation (K479N) in the icSZ16-S spike protein allows
for passage of icSZ16-S K479N virus into Vero E6 cells.
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Similarly to the HAE model, early growth of the icSZ16-S
K479N D22 virus was more rapid than that of the icSZ16-
S K479N D8 virus in DBT-hACE2, but the growth of
icSZ16-S K479N D8 virus never matched the icSZ16-S
K479N D22 virus growth even after 36 hpi (Fig. 3C). Simi-
larly to the HAE model, the icSZ16-S K479N p3 and the
icSZ16-S K479N p6 viruses replicated poorly in DBT-hACE2
cells, reaching titers of only 103 PFU/ml by 36 hpi (Fig. 3C).
DBT cells did not support the replication of any of the viruses
within our panel, which supports the hypothesis that the ex-
pression of ACE2 within DBT-hACE2 cells is required for the
growth of all viruses within our panel (Fig. 3D).
Immunohistochemistry of infected HAE cells. Host range
expansion of other coronaviruses resulted in a change in cell
tropism that was oftentimes associated with a change in recep-
tor usage (4, 27). To determine the types of cells infected by
the panel viruses in HAE, infected cultures were fixed and
sectioned for the histological staining of SARS-CoV nucleo-
capsid antigen and tubulin for the staining of cilia. SARS N
antigen was not detected in mock-infected cultures, though
cilia on the apical surface of ciliated epithelial cells show bright
staining (Fig. 4A). SARS N antigen is readily detected within
the ACE2-expressing ciliated cells of icSARS (Fig. 4B)- and
icSZ16-S K479N D22 (Fig. 4D)-infected cell cultures but is
only sporadically detected in icSZ16-S K479N p6 (Fig. 4C)-
infected cell cultures. Nevertheless, the HAE-evolved icSZ16-S
K479N D22 virus and the parent zoonotic icSZ16-D K479N
virus encode ciliated cell tropisms that are similar to those seen
in late-phase epidemic strains.
PRNT using human MAb S230.15. Future outbreaks of
SARS-CoV would most likely emerge from pools of zoonotic
virus, and it is imperative that vaccinations or serotherapies be
effective against both past and future emergent zoonotic
strains. S230.15 is a human MAb that is broadly neutralizing
through its binding to the RBD, though the specific location of
the epitope is unknown (48, 59). The epidemic strain and the
evolved icSZ16-S K479N D8 and icSZ16-S K479N D22 viruses
are equally neutralized by S230.15 (50% neutralization at a
concentration between 0.0625 and 0.125 g/ml), but icSZ16-S
K479N is eight times more resistant (50% neutralization at 0.5
g/ml) (Fig. 5). Since icSZ16-S K479N and the evolved
FIG. 3. Growth curve analysis of the mutant virus panel in HAE,
Vero E6, DBT-hACE2, and DBT cells. (A) HAE cell cultures were
infected with 4.4  104 PFU/200 l of the indicated viruses for 2 h at
37°C. The inoculum was removed, and the apical surfaces were rinsed
with DPBS. Apical-surface washes were performed at 0, 6, 12, 24, 36,
48, and 72 hpi. Virus titers were assessed for Vero E6 cells by a
standard plaque assay. (B to D) Vero E6, DBT-hACE2, and DBT cells
(respectively) were infected with the indicated viruses at an MOI of
0.01 for 1 h at 37°C. The inoculum was removed, cultures were rinsed
with DPBS, and growth medium was added. The medium was sampled
at 0, 6, 12, 24, and 36 hpi, and virus titer was assessed by plaque assay
on Vero E6 cells. The data presented are representative of two sepa-
rate experiments.
FIG. 4. Immunofluorescence staining of HAE cell cultures infected with the mutant virus panel. At 72 hpi, mock and infected HAE cell cultures
were PFA fixed and paraffin embedded for tissue sectioning. Sections were stained for SARS-CoV N (fluorescein isothiocyanate) and tubulin
within cilia (Texas Red) and viewed by fluorescence microscopy. (A) Mock; (B) icSARS; (C) icSZ16-S K479N; (D) icSZ16-S K479N D22.
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icSZ16-S K479N D8 virus only differ in 1 amino acid within the
S protein, these data suggest that the S230.15 epitope resides
near residue 442. Moreover, these data suggest that as SZ16-
like zoonotic SARS-CoVs adapt to the hACE2 receptor in the
human airway, they may become more susceptible to S230.15
neutralization, especially if they evolve with mutations at res-
idue 442. As an isotype control, an irrelevant cholera-toxin-
specific antibody (D2.2) was used in a PRNT assay with the
mutant virus panel, and none of the viruses were neutralized at
any concentration of the antibody (data not shown).
The icSZ16-S K479N and icSZ16-S K479N D22 viruses rep-
licate in the lungs of young BALB/c mice but do not cause
clinical signs in young or senescent BALB/c mice. Since the
epidemic strain may not exist in nature and future epidemic
SARS-CoV strains would most likely evolve from zoonotic
pools of virus, it is prudent to employ an antigenically diver-
gent panel of zoonotic challenge viruses to assess their thera-
peutic efficacies and cross-reactivities. To this end, it is imper-
ative that the challenge viruses behave similarly in current
animal models used to assess vaccine efficacy. Infection of
young BALB/c mice with SARS Urbani typically does not
cause clinical symptoms (5, 39). Young mice that were either
mock infected or infected with the icSARS, icK479N-S K479N,
or icSZ16-S K479N D22 viruses did not lose weight or present
with other clinical signs (Fig. 6A). Clinical outcomes in senes-
cent mice infected with icSZ16-S K479N or icSZ16-S K479N
D22 mirrored those of young mice, with senescent mice losing
little to no weight following infection (data not shown). The
icSZ16-S K479N and icSZ16-S K479N D22 viruses replicated
in the lungs of young BALB/c mice to titers similar to the
epidemic strain on day 2 postinfection (3  106 PFU/g) (Fig.
6B). By day 4 postinfection, the titers of the civet viruses were
about 1 log lower than the epidemic strain, suggesting that the
civet viruses might be cleared more rapidly (Fig. 6B).
Rosetta Design modeling of S RBD and ACE2 interactions.
Rosetta Design was used to model hACE2’s interactions with
the RBDs of the SZ16, SZ16 K479N, icSZ16-S K479N D8, and
icSZ16-S K479N D22 viruses. In contrast to the epidemic
strain N479 residue, the SZ16 K479 residue appears to elec-
trostatically clash with the ACE2 binding partners K31 and
H34. After a point mutation (K479N) is introduced in the civet
S RBD, the repulsive forces of the civet K479 are eradicated,
allowing for S and ACE2 binding (Fig. 7A, B, and C). The
Urbani RBD residues 442 and 479 are predicted to have single
hACE2 binding partners (residue 442 interacts with H34; res-
idue 479 interacts with K31) (Fig. 7A). Though residues 442
and 479 of the SZ16 K479N RBD are identical to Urbani,
residues 442 and 479 are predicted to compete for hACE2
binding partner H34, and residue 442 is also predicted to
interact with H34 and K31 of hACE2 (Fig. 7C). The difference
in binding efficiencies of the seemingly similar Urbani and
K479N RBDs is likely due to subtle alterations of the RBD
hydrogen bonding network created by mutations at the periph-
eral RBD residue 487. Residue S487 of the SZ16 K479N RBD
binds to one ACE2 residue, but T487 of Urbani binds to three
residues of ACE2, thereby enhancing S and ACE2 binding
interactions (Fig. 7C). The Rosetta Design model predicts that
the Y442F mutation within the icSZ16-S K479N D8 S protein
creates an RBD architecture similar to that of SARS Urbani,
where S residues F442 and N479 have singular and unique
hACE2 binding partners (residue 442 binds K31 of hACE2,
and residue 479 binds H34 of hACE2) while retaining the S487
and Y41 interaction and the hydrogen bonding network (Fig.
7C and D). Finally, while the icSZ16-S K479N D8 L472 residue
is predicted to have only two potential ACE2 binding partners
(L79 and M82), the L472F mutation of the icSZ16-S K479N
D22 S protein is predicted to increase the numbers of possible
binding partners of ACE2 to three residues (L79, M82, and
Y83), thereby strengthening S binding (Fig. 7D and E).
DISCUSSION
The past and present sporadic reemergences of the Chikun-
gunya, Ebola, and Nipah viruses highlight the severe patho-
genic and epidemic potential of zoonotic viruses, and the iden-
tification of the animal reservoir host is often elusive (13, 20,
25, 47, 51). Live-animal markets in China and elsewhere have
FIG. 5. PRNT assay of the mutant panel viruses using human MAb
S230.15. One hundred PFU of the indicated virus was incubated at
37°C for 1 h with twofold dilutions of antibody or DPBS in duplicate.
After the incubation, the virus-antibody cocktails were used to infect
Vero E6 cell monolayers for 1 h, after which cultures were overlaid
with growth medium containing agarose. After 48 h, plaques were
enumerated. The percentages of neutralization were calculated as fol-
lows: 1  (number of plaques with antibody/number of plaques with-
out antibody)  100%. Error bars represent the standard errors of the
means.
FIG. 6. Clinical signs and lung virus titers of 6-week-old BALB/c
mice infected with DPBS, icSARS, icSZ16-S K479N, or icSZ16-S
K479N D22. (A) Mice were infected with 105 PFU/50 l intranasally
(10 mice per virus), and weight was monitored daily. (B) Lungs were
removed on days 2 and 4 postinfection (3 mice per group per day),
homogenized, and centrifuged to pellet debris. Supernatants were used
in a standard plaque assay to determine lung virus titers (PFU/g).
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been proven to be an important factor in cultivating food-
borne illnesses and cross-species transmission of SARS-CoV,
avian influenza viruses, and other pathogens (29, 54, 55).
Within the live-animal markets of China, dense human and
animal populations mix, creating an environment ripe for the
exchange of viruses from animals to humans and from humans
to animals. During the SARS-CoV epidemic, the Himalayan
palm civet was identified as the principal source of the SARS-
CoV zoonosis even though 1,107 civets on farms that supplied
the markets tested negative, suggesting that the civets were
infected within the markets (16). Moreover, sequence analysis
of bat- and civet-associated SARS-CoV has provided more
definitive evidence that bat-associated SARS-CoV jumped the
species barrier to infect civets and that bat and civet viruses are
similar yet distinct from late-phase epidemic strain isolates (2,
9, 18, 26, 34, 41).
After the identification of ACE2 as the cellular receptor for
SARS-CoV, several investigators have defined the molecular
determinants of the virus and receptor interactions that al-
lowed for the epidemic SARS-CoV host expansion. Prior to
this report, key residues in the civet S gene responsible for
changes in the host range were identified using SARS-CoV S
pseudotyped retroviruses, but these results had not yet been
confirmed in the context of wild-type SARS-CoV infection in
vivo or in vitro. In support of data from Li et al., we demon-
strate that the civet-spiked icSZ16-S virus was capable of a
FIG. 7. Rosetta Design modeling of “evolved” mutations that enhance spike protein binding to ACE2. Rosetta Design was used to generate
structural models of SZ16 and mutant RBDs that were then superimposed onto the existing crystal structure of the SARS Urbani RBD bound to
ACE2. (A) Epidemic strain and hACE2 RBD architecture. (B) SZ16 and hACE2 interaction is inhibited by steric clashing, shown as red dots, of
K479 of S and residues K31 and H34 of hACE2. (C) Electrostatic repulsion at residue 479 is eradicated, allowing S and ACE2 binding, but local
remodeling within the RBD due to hydrogen bonding differences at residue 487 creates cross-reactions whereby residues 442 and 479 of K479N
compete with each other for interaction partners H34, K31, and D32 of hACE2. (D) The Y442F mutation of icSZ16-S K479N D8 restores an
optimal RBD, allowing for favorable packing to create an architecture similar to that of the wild type. (E) Leucine 472 of the icSZ16-S K479N
and icSZ16-S K479N D8 S interacts with L79 and M82 of ACE2. The icSZ16-S K479N D22 L472F mutation is predicted to have hydrophobic
interactions with three potential partners, L79, M82, and Y83, of hACE2 that will increase the stability of the binding. Green dots on hACE2
indicate residues which are within 4 angstroms and thus are predicted to interact with the S residues shown in red.
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single round of replication following transfection of full-length
genomic RNA but was incapable of infecting naive Vero E6
cells in subsequent rounds of infection (21). However, the
introduction of a single amino acid mutation (K479N) in the
icSZ16-S virus S protein allowed for low-level spread and pas-
sage in Vero E6 cells. Both icSZ16-S K479N p3 and p6 viruses
grew similarly in Vero and DBT-hACE2 cells, suggesting that
the slight differences in their abilities to cause CPE did not
affect virus binding, entry, or replication fitness during the time
observed and at the MOI used in our assays. Though we did
not use icSZ16-S K479N p6 in our HAE cell growth studies, we
would expect both p3 and p6 isolates to perform similarly,
since their growth kinetics in Vero and DBT-hACE2 cells were
similar. Importantly, the K479N mutation did not result in a
virus capable of efficient replication in HAE or DBT-hACE2
cells, supporting the argument that additional mutations are
required to enhance the SZ16 S interaction with the human
ACE2 receptor. The differences seen in icSZ16-S K479N
growth in HAE and Vero E6 cells highlight the strength and
relevance of the HAE model of the human airway. Even
though the contact residues of primate and human ACE2 are
predicted to be similar, the differences in icSZ16-S K479N
growth in HAE and Vero E6 cells suggest that differences in
primate and human ACE2 proteins (89% similar on the amino
acid level) subtly influence binding efficiency or that the abun-
dance of mucus and a unique extracellular matrix on the sur-
faces of HAE cells differentially antagonize virus entry. Thus,
in order to study and model S protein and hACE2 interactions,
HAE or DBT-hACE2 cells should be used as more relevant
alternatives to Vero E6 cells. Importantly, the expression of
hACE2 in a nonpermissive DBT cell line rendered these cells
permissive for icSARS, icSZ16-S K479N, icSZ16-S K479N D8,
and icSZ16-S K479N D22 virus infection, which strongly sup-
ports earlier hypotheses that ACE2 is the principal receptor
required for the docking and entry of both human and zoonotic
strains (24).
For both the canine parvovirus (CPV) and the 1918 Spanish
influenza virus H1N1, point mutations in the viral structural
proteins responsible for binding to the host cell were sufficient
to catalyze host range expansion (14, 46). In 1978, two muta-
tions in the capsid protein of feline parvovirus that were suf-
ficient to catalyze host expansion evolved, causing severe ca-
nine infection and a worldwide epidemic of CPV-naive canine
populations (14, 32). In 1918, the zoonotic H1N1 influenza
virus acquired two mutations in hemagglutinin, changing the
preferential binding from the avian to the human sialic acid
receptor. When the hemagglutinin mutations were coupled
with a few additional mutations in the genome, a human pan-
demic ensued with estimated deaths of 20 million to 40 million
(32, 46). Similarly to those of the CPV and H1N1 viruses,
analyses of the zoonotic and human SARS-CoV S sequences
show a logical progression of S protein mutations that most
likely fostered host range expansion and increased human
pathogenesis (16). Of the 14 amino acids of S that contact 18
amino acids of ACE2, the K479N and S487T mutations have
been shown to be equally essential for civet S adaptation to
human ACE2 (21). The K479N mutation removed an electro-
static clash, allowing the S protein RBD to interact with human
ACE2, while S487T appears to have subtly remodeled the
RBD through hydrogen bonding differences that optimized
hACE2 binding. Considering our in vitro evolution data and
sequence data from the SARS epidemic, we hypothesize that
at least two independent mutational pathways can optimize
hACE2 binding. The first was observed during the epidemic,
where the S487T mutation optimized binding as described
above. The second route occurred during our in vitro evolu-
tion, whereby the Y442F mutation optimized hACE2 binding
in the presence of the S487 variant. ACE2-expressing ciliated
epithelial cells in the airway are targets for SARS-CoV infec-
tion in humans, primate and rodent models making the HAE
model an important in vitro system for studying the molecular
mechanisms of animal S adaptation to the human host (10, 11,
30, 38, 39). Since the icSZ16-S virus could not be propagated
in Vero E6 cells, we introduced the K479N point mutation in
the virus S that was sufficient to allow multiple rounds of
replication of the civet-spiked icSZ16-S K479N virus in cell
culture. Passage of the icSZ16-S K479N recombinant virus in
HAE cells resulted in the emergence of S variants that could
replicate more efficiently. Surprisingly, S487T was not selected
with the passage of SZ16 K479N, but new mutations evolved
within contact residues of the icSZ16-S K479N D8 and
icSZ16-S K479N D22 virus RBDs (Y442F and L472F) that
enhanced virus infection of HAE, Vero E6, and DBT-hACE2
cells. To rule out non-receptor-specific cell culture adaptations
that enhance entry into cells in vitro, we infected DBT cells
and did not see evidence of virus growth with any of the viruses
tested. Moreover, our immunohistochemistry of infected HAE
cell cultures (Fig. 4) suggests that in vitro-evolved viruses and
the epidemic strain infect similar cell types, providing further
support that non-receptor-specific entry adaptations had not
occurred in our model. Recent passage of a related coronavi-
rus, mouse hepatitis virus, in cell lines resulted in variants with
an expanded host range due to the acquisition of a common
non-receptor-specific cell culture adaptation using heparin sul-
fate for virus entry into cells (4). Most recently, McRoy and
Baric demonstrated that the passage of mouse hepatitis virus
in cell lines resulted in an expanded host range through mu-
tations within the fusion peptide and heptad repeats, demon-
strating that host range can be governed by changes in spike
fusogenicity (27). From sequence analysis, we concluded that
the in vitro evolved mutations of icSZ16-S K479N had not
created a heparin consensus binding site (XBXBBX) and that
our adaptive mutations were constrained to the RBD.
To determine the potential impact of the mutations acquired
during HAE passage, we used Rosetta Design to generate
structural models of the SZ16, icSZ16-S K479N, icSZ16-S
K479N D8, and icSZ16-S K479N D22 RBDs and then super-
imposed these models onto the existing crystal structure of the
SARS Urbani RBD bound to hACE2 (PDB code 2AJF) (Fig.
7A). Similarly to Li et al., we observed that residue K479 of the
SZ16 S inhibited binding to hACE2 by sterically clashing with
residues K31 and H34 (Fig. 7B). After the K479N mutation,
the electrostatic repulsion at residue 479 is eradicated, but
Rosetta Design predicts that local remodeling within the RBD
creates cross-reactions whereby residues 442 and 479 of the
K479N RBD compete with each other for interaction with
partners H34, K31, and D32 of ACE2 (Fig. 7C). It appears that
Y442 could interact with all three hACE2 residues, but N479 is
predicted to interact only with H34 of hACE2. We predict that
this network of competing interactions reduces the avidity be-
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tween the K479N RBD and the hACE2 receptor by misalign-
ing other key residues in the RBD. Of note, the only difference
in the RBDs of SZ16 K47N and Urbani occurs at position 487.
The fact that SZ16 K479N is compromised in growth com-
pared to Urbani suggests that the hydrogen bonding differ-
ences between S487 of SZ16 K47N and Thr487 of Urbani
influence the receptor interaction. During the 2003 epidemic,
S487T likely evolved to eliminate this putative inhibitory effect.
Interestingly, the icSZ16-S K479N D8 Y442F mutation also
restores an optimal RBD by allowing for favorable amino acid
packing that recreated an RBD architecture similar to that of
the wild type (Fig. 7A and D). In this case, the icSZ16-S K479N
D8 RBD residues 442 and 479 have distinct and unique inter-
action partners in hACE2, which likely restores avidity to near
wild-type levels and may explain why the icSZ16-S K479N D8
virus grows more efficiently than the icSZ16-S K479N virus in
cells expressing hACE2 (Fig. 3C and 7D). Thus, at least two
independent routes of evolution could increase S RBD and
human ACE2 interactions. Leucine 472 of the icSZ16-S
K479N RBD and the icSZ16-S K479N D8 RBD interacts with
L79 and M82 of ACE2. The icSZ16-S K479N D22 virus RBD
is mutated at position 472 from leucine to phenylalanine,
which Rosetta Design predicts will induce strong hydrophobic
interactions between F472 and partners L79, M82, and Y83 of
ACE2 (Fig. 7E). The icSZ16-S K479N D22 virus F472 muta-
tion likely strengthens the binding interface of the icSZ16-S
K479N D22 virus over the icSZ16-S K479N D8 strain, which
may explain why the icSZ16-S K479N D22 virus has a growth
advantage over the icSZ16-S K479N D8 virus in HAE, Vero
E6, and DBT-hACE2 cells. Of note, it is possible that these
viruses acquired replication-enhancing mutations in structural
or nonstructural genes that we did not sequence. Nevertheless,
these data demonstrate the plasticity of the RBD-ACE2 inter-
face site and its ability to subtly remodel the RBD and hACE2
binding interface to promote efficient entry and growth.
Clearly, multiple genetic pathways likely exist to allow for
zoonotic SARS-CoV host range expansion, and it will be in-
teresting to determine if other contact interface point muta-
tions can enhance zoonotic virus infection of HAE cell cul-
tures.
Since viruses similar to the epidemic strain are currently
circulating in bats in China, we may see yet another emergence
of human SARS-CoV from zoonotic pools of virus. Therefore,
it is imperative that current vaccinations and passive serother-
apies be effective against all known SARS-CoV zoonotic
strains and their human-adapted progeny. Previous work by
Deming et al. has highlighted the value of using zoonotic
strains as challenge viruses to assess vaccine efficacy (5). Dem-
ing et al. demonstrated that sera from animals vaccinated with
epidemic strain antigens were not as effective in neutralizing
the zoonotic icGD03-S virus as they were in neutralizing the
epidemic strain (5). Within this study, we demonstrated that
two zoonotic spiked viruses, icSZ16-S K479N and icSZ16-
K479N D22, grew to peak titers in the mouse lung similar to
those of the epidemic strain 2 days postinfection. In contrast to
recombinant SARS-CoV bearing early human (GZ02) or civet
S glycoprotein (HC/SZ/61/05) S proteins that were extremely
pathogenic in aged animals, icSZ16-S K479N and icSZ16-S
K479N D22 caused little to no disease in either young or
senescent BALB/c mice (40). Although the SZ16 and HC/SZ/
61/03 viruses are both of civet origin, their S proteins differ by
18 amino acids (9; G. Yi, SARS coronavirus HC/SZ/61/03
complete genome). The 7-month period of time between the
isolation of SZ16 (May 2003) and the isolation of HC/SZ/61/03
(December 2003) may help explain their sequence differences
(9; G. Yi, SARS coronavirus HC/SZ/61/03 complete genome
[http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?dbnuccore&id
42556132]). Zoonotic SARS-CoV infection of humans is typ-
ically less severe than infection with human strains, but it is
possible that the sequence differences between the SZ16 and
the HC/SZ/61/03 S proteins alter the structure of the S proteins
such that the viruses bearing the HC/SZ/61/03 S are lethal in
mice, while our SZ16 lineage viruses are attenuated (2, 9, 19,
23, 40, 45). Nevertheless, the icSZ16-S K479N and icSZ16-S
K479N D22 viruses grow to levels similar to those of the
epidemic strain in mice and could be useful as challenge vi-
ruses to assess the efficacies of vaccines or serotherapies. The
human MAb S230.15 binds within the RBD, although the
specific epitope has yet to be defined (48, 59). Recent data
from Traggiai et al. and Zhu et al. have shown MAbs S230.15
and, to a lesser extent, m396 to be potent and cross-neutraliz-
ing antibodies against human and zoonotic SARS-CoV isolates
(48, 59). We have demonstrated that the “evolved” icSZ16-S
K479N D8 and D22 viruses were equally susceptible to neu-
tralization by S230.15 but that icSZ16-S K479N was eight times
more resistant. In this instance, these data suggest that zoo-
notic virus adaptation to the human ACE2 receptor may en-
hance susceptibility to neutralization by S230.15. Since there
was a dramatic difference in neutralization between icSZ16-S
K479N and icSZ16-S K479N D8, these data suggested that the
epitope of S230.15 is in close proximity to or was affected by
structural changes associated with residue 442 of the S protein.
Future efforts to revive the divergent wild-type icSZ16-S virus
in vitro will be especially helpful with mapping the S230.15
epitope, since it is possible that the K479N mutation may
contribute to enhanced S230.15 binding. Even though S230.15
is less effective at neutralizing icSZ16-S K479N in vitro, re-
cently published passive transfer studies in mice have shown
that the S230.15 antibody is extremely potent and broadly
neutralizing in vivo where replication of SARS Urbani,
icGD03-S, and icSZ16-S K479N were not detected in the
mouse lung (59). These data highlight the power and utility of
zoonotic strains in assessing the efficacy of passive serotherapy
both in vitro and in vivo.
In conclusion, synthetic biology has been employed to rap-
idly construct and assemble a completely synthetic and infec-
tious 5.3-kb bacteriophage, poliovirus, 1918 influenza virus,
and a panel of SARS viruses bearing animal and human S
glycoproteins (1, 5, 40, 44, 49). We provide yet another exam-
ple of the utility of synthetic biology by resurrecting the civet
SZ16 S. We have shown that a single point mutation (K479N)
in the SZ16 S facilitates host range expansion, but additional
mutations must occur for robust infection of human cells. Mu-
tations of residues 479 (K479N) and 487 (S487T) occurred
during the early phase of the SARS-CoV epidemic to help
facilitate host range expansion. Though we did not generate a
mutant SZ16 S containing S487T, previous studies have shown
that the inclusion of a mutation at either position 479 or 487 in
pseudotype virus bearing the civet S allowed for the infection
of human cells, but this approach provides little information on
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growth efficiency and spread. Through our in vitro evolution of
the icSZ16-S K479N virus, we discovered a novel evolutionary
path by which SARS-CoV S can interface with hACE2 to allow
for the efficient infection of human cells. When S mutations
acquired during our in vitro evolution are compared to muta-
tions that occurred during the evolution of the epidemic strain,
the plasticity of the SARS-CoV S protein becomes starkly
apparent. Through the use of HAE cell cultures, synthetic
biology, reverse genetics, and animal models, we have created
a system to isolate and characterize novel genetic pathways of
zoonotic SARS-CoV S adaptation to the human ACE2 recep-
tor. We have also generated antigenically divergent SARS-
CoV zoonotic strains that might be useful in assessing the
efficacies of SARS-CoV vaccines or serotherapies. Since the
future emergence of SARS-CoV will most likely evolve from
zoonotic pools of virus, it is imperative that current vaccina-
tions and passive serotherapies be effective against the zoo-
notic virus, the epidemic virus strain, and all of the evolution-
ary permutations in between.
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